The estimated Net Worth of Gregory T. Mayes, is at least $2.18 Миллион dollars as of 25 October 2016. Mr. Mayes owns over 19,162 units of AVEO Pharmaceuticals Inc stock worth over $1,546,305 and over the last 11 years he sold AVEO stock worth over $539,063. In addition, he makes $93,400 as Independent Director at AVEO Pharmaceuticals Inc.
Gregory has made over 3 trades of the AVEO Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 19,162 units of AVEO stock worth $157,703 on 25 October 2016.
The largest trade he's ever made was selling 19,231 units of AVEO Pharmaceuticals Inc stock on 26 October 2015 worth over $223,657. On average, Gregory trades about 1,066 units every 7 days since 2013. As of 25 October 2016 he still owns at least 103,087 units of AVEO Pharmaceuticals Inc stock.
You can see the complete history of Mr. Mayes stock trades at the bottom of the page.
Gregory T. Mayes J.D. serves as Independent Director of the Company. Mr. Mayes is the president and chief executive officer of Engage Therapeutics, Inc., a privately held specialty biopharmaceutical company, which he founded in January 2017. From January 2018 to April 2019, Mr. Mayes served on the board of OncoSec Medical Incorporated, a public biopharmaceutical company. From 2013 to 2016, Mr. Mayes served as executive vice president and chief operating officer of Advaxis, Inc., a public biotechnology company focused on the development of immune-oncology therapies. Mr. Mayes also served on the board of Advaxis, Inc. from March 2016 to April 2017. Prior to joining Advaxis, Inc., Mr. Mayes served as executive vice president of Dendreon Corporation, a public biotechnology company. From 2010 to 2012, Mr. Mayes was the president and general counsel of Unigene Laboratories, Inc. where he primarily led out-licensing efforts for its oral peptide drug delivery platform. He also served on the board of Unigene Laboratories, Inc. from 2012 to 2013. Prior to these roles, Mr. Mayes served as general counsel and chief compliance officer at ImClone Systems Corporation, a wholly owned subsidiary of Eli Lilly & Company, and as senior counsel at AstraZeneca Pharmaceuticals, LP., and practiced law at Morgan, Lewis & Bockius LLP. He holds a B.S. in advertising and political science from Syracuse University and a J.D. from the Temple University School of Law.
As the Independent Director of AVEO Pharmaceuticals Inc, the total compensation of Gregory Mayes at AVEO Pharmaceuticals Inc is $93,400. There are 5 executives at AVEO Pharmaceuticals Inc getting paid more, with Michael Bailey having the highest compensation of $1,589,640.
Gregory Mayes is 51, he's been the Independent Director of AVEO Pharmaceuticals Inc since 2019. There are 11 older and 2 younger executives at AVEO Pharmaceuticals Inc. The oldest executive at AVEO Pharmaceuticals Inc is Robert Young, 80, who is the Independent Director.
Gregory's mailing address filed with the SEC is C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON, MA, 02108.
Over the last 15 years, insiders at AVEO Pharmaceuticals Inc have traded over $6,664,465 worth of AVEO Pharmaceuticals Inc stock and bought 153,034,058 units worth $217,351,881 . The most active insiders traders include Forest Baskett, Scott D Sandell и Anthony A. Jr. Florence. On average, AVEO Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $9,488,415. The most recent stock trade was executed by Michael P Bailey on 20 December 2022, trading 276,746 units of AVEO stock currently worth $1,248,124.
AVEO Pharmaceuticals Inc. is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO's strategy is to focus its resources toward the development and commercialization of its product candidates in North America, while leveraging partnerships to support development and commercialization in other geographies. AVEO's lead candidate, FOTIVDA® (tivozanib), received U.S. Food and Drug Administration (FDA) approval on March 10, 2021 for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA® was approved in August 2017 in the European Union and other countries in the EUSA territory for the treatment of adult patients with advanced RCC. AVEO has previously reported promising early clinical data on ficlatuzumab (anti-HGF IgG1 mAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia and is conducting a randomized Phase 2 confirmatory clinical trial of ficlatuzumab for the potential treatment of head and neck cancer. AVEO's pipeline of product candidates also includes AV-380 (anti-GDF15 IgG1 mAb). AVEO has previously reported the acceptance of its investigational new drug application in the U.S. for AV-380 and its initiation of a Phase 1 clinical trial for the potential treatment of cancer cachexia. AVEO's earlier-stage pipeline includes monoclonal antibodies in oncology development, including AV-203 (anti-ErbB3 mAb) and AV-353 (anti-Notch 3 mAb). AVEO is committed to creating an environment of diversity and inclusion.
AVEO Pharmaceuticals Inc executives and other stock owners filed with the SEC include: